The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01317186

Enrollment

100

Registered

2011-03-17

Start date

2011-03-31

Completion date

Unknown

Last updated

2011-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Metabolic Diseases

Keywords

FGF 23, ADMA, chronic kidney disease, Ca-P metabolism disorder

Brief summary

In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Interventions

None listed

Study design

Observational model

COHORT

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* between ages of 18 - 65 years old * chronic kidney disease of stage 2-4

Exclusion criteria

* presence of diabetes mellitus or ischemic hearth disease * taking vitamin d therapy

Countries

Turkey (Türkiye)

Outcome results